Off-the-shelf NK Cells (KDS-1000) as Immunotherapy for COVID-19

Inclusion Criteria: 1. Patients are 18-70 years of age; 2. Patients must have at least one of the following risk factors for developing severe COVID-19 disease: 1. Age 50 to 70 years; 2. Obesity (body mass index (BMI) of 30 or greater); 3. Hypertension; 4. Current smoker; 5. Diabetes mellitus (Type 1 or type 2); 6. Stable cardiac disease. 3. Experiencing symptoms of mild to moderate COVID-19 not requiring supplemental oxygen; 4. Having confirmed infection with SARS-CoV-2, defined as detection of SARS-CoV-2 from nasopharyngeal swab or lower respiratory tract specimen; 5. Karnofsky Performance Score ≥70%; 6. Enrolled within the first 4 days of onset of symptoms; 7. Able and willing to comply with the protocol for duration of the study, including 24 hour hospitalization for study drug administration and monitoring, and compliance with follow-up visit schedule; 8. Signed IRB approved informed consent. Exclusion Criteria: 1. Patient is at high-risk for severe COVID-19 due to co-morbidities defined as: 1. Underlying lung disease such as emphysema, chronic lung disease, COPD, asthma, chronic bronchiectasis or respiratory failure requiring baseline oxygen (O2) support; 2. Immunocompromised host status due to cancer, transplant, or other causes of immunodeficiency; 3. Immunosuppressive therapy, including but not limited to the following: * Corticosteroids (except topical corticosteroids); * Interleukin (IL)-6 or Tumor necrosis factor alpha (TNFα) blockade; * Other immunotherapies. 2. Patient with the following signs of abnormal organ or bone marrow function as defined below: * AST(SGOT) and/or ALT(SGPT) \> 3 x upper limit of normal (ULN); * Serum (total) bilirubin \> 1.5 x ULN; * Creatinine Clearance ≤ 30 mL/min (by Modification of Diet in Renal Disease (MDRD) formula); * Hemoglobin \< 9 g/dL; * Thrombocytes ≤ 75.000/uL; * Absolute neutrophil count (ANC) ≤ 1.500/uL; * Prothrombin time (PT) or activated partial thromboplastin (aPTT) time \>1.5 × ULN; 3. Patient has been admitted to the (ICU); 4. Patients with QT prolongation, history of "torsades de pointes" or ventricular arrhythmia (if they are scheduled to receive diphenhydramine); 5. Patient with a known history of allergic reactions to any constituent of the product, including a known history of allergic reactions to cellular products or DMSO; 6. Pregnant (positive pregnancy test) or breast-feeding female patients; 7. Women of childbearing potential who are sexually active and men who have sexual contact with a female of childbearing potential: not willing to use reliable methods of contraception (oral contraceptives, intrauterine device, hormone implants, contraceptive injection or abstinence) up to 90 days post injection of study medication; 8. Participation in other COVID-19 studies involving experimental treatments or vaccines for COVID-19. Participation in other observational studies could be allowed if they do not interfere with protocol compliance or blood draws; 9. Patients with a history or current evidence of alcohol or drug abuse or dependence, or recreational use of illicit drugs including use of medical marijuana; 10. Vulnerable populations such as those currently incarcerated or homeless; 11. Any other condition which in the opinion of the investigator makes the patient ineligible for participation in the study.